EIF4E Antibody

What is eIF4E and why is it a significant target for antibody-based research?

eIF4E is a cap-binding protein that plays a critical role in translation initiation by recognizing the 7-methylguanosine cap structure present on the 5' end of messenger RNAs. This interaction is crucial for cap-dependent translation, making eIF4E a regulatory hub for protein synthesis.

The significance of eIF4E as a research target stems from several factors:

• eIF4E functions as a critical node in oncogene-driven protein synthesis, making it a promising anticancer target

• It controls gene expression through dual effects on mRNA export and cap-dependent translation, both contributing to its oncogenic potential

• eIF4E phosphorylation status correlates with translational activity in most cellular contexts

• eIF4E is a direct transcriptional target of NF-κB in hematopoietic cells, with dysregulation observed in acute myeloid leukemia (AML)

Antibodies targeting eIF4E enable researchers to investigate these functions through various techniques including Western blotting, immunofluorescence, immunoprecipitation, and chromatin immunoprecipitation.

How can researchers validate the specificity of an eIF4E antibody?

Validation of eIF4E antibody specificity is critical to ensure experimental reliability. A methodological approach includes:

• Western blot analysis: Run samples from wild-type cells alongside eIF4E-knockout or knockdown controls. A specific antibody will show reduced or absent signal in the knockdown/knockout samples.

• Multiple antibody verification: Use multiple antibodies targeting different epitopes of eIF4E to confirm consistent detection patterns.

• Phospho-specific validation: For phospho-specific eIF4E antibodies, treat samples with phosphatases prior to Western blotting to confirm specificity to the phosphorylated form .

• Peptide competition assay: Pre-incubate the antibody with a synthetic peptide containing the target epitope before application to samples. Signal reduction confirms specificity.

• Cross-reactivity assessment: Test antibody against recombinant eIF4E proteins from different species to determine cross-reactivity profiles.

Example of validation by Western blot:

• Use wild-type and transgenic lines expressing eIF4E variants

• Include proper loading controls (e.g., anti-eIF4A)

• Verify that antibody binds to the expected isoform and that signal intensity correlates with known expression levels

What are the optimal conditions for using eIF4E antibodies in immunofluorescence applications?

For successful immunofluorescence with eIF4E antibodies, researchers should consider the following methodological approaches:

• Fixation method:

  • Paraformaldehyde (4%) for 15-20 minutes at room temperature preserves most epitopes

  • For phospho-specific eIF4E antibodies, include phosphatase inhibitors in fixation buffers

• Permeabilization:

  • 0.1-0.5% Triton X-100 for 10 minutes is typically sufficient

  • For examining nuclear eIF4E, ensure complete nuclear permeabilization

• Blocking conditions:

  • 5-10% normal serum (species of secondary antibody) with 1% BSA

  • Include 0.1% Tween-20 to reduce background

• Antibody concentration:

  • Primary antibody dilution should be optimized (typically 1:100 to 1:500)

  • For Human/Mouse/Rat eIF4E Antibody (MAB3228), a concentration of 10 μg/mL has been validated for detection in MCF-7 human breast cancer cells

• Incubation conditions:

  • 1-3 hours at room temperature or overnight at 4°C for primary antibody

  • 1 hour at room temperature for fluorophore-conjugated secondary antibody

• Controls:

  • Include secondary-only controls

  • Use cells with known eIF4E expression patterns

  • Consider knockdown/knockout controls

When examining subcellular distribution, remember that eIF4E can localize to both nuclear and cytoplasmic compartments, with distinct functional roles in each .

How can researchers effectively use eIF4E antibodies to study phosphorylation-dependent regulation?

eIF4E phosphorylation status correlates with translational activity in most cells, making it a critical regulatory mechanism to investigate. A comprehensive approach includes:

• Phospho-specific antibody selection:

  • Use antibodies that specifically recognize phosphorylated Ser209 (the major phosphorylation site in mammals)

  • For studying Aplysia californica eIF4E, specific antibodies to its phosphorylated form have demonstrated correlation between translation rates and phosphorylation increases

• Sample preparation protocol:

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all buffers

  • Use rapid sample processing to prevent post-lysis dephosphorylation

  • Consider using SDS-PAGE with Phos-tag™ acrylamide for enhanced separation of phosphorylated species

• Experimental designs to monitor dynamic changes:

  • Time-course studies following stimulation with growth factors or stress induction

  • Coordinate phosphorylation analysis with translation rate measurements

  • Compare with treatments using specific kinase inhibitors (e.g., MNK inhibitors)

• Quantification methods:

  • Use quantitative Western blotting with both phospho-specific and total eIF4E antibodies

  • Calculate phospho-eIF4E/total eIF4E ratio to normalize for expression differences

• Functional correlation:

  • Combine with polysome profiling to correlate phosphorylation state with translation activity

  • Use phosphomimetic (S209D) and phosphodeficient (S209A) eIF4E mutants to validate functional significance

Remember that while increased eIF4E phosphorylation generally correlates with increased translational activity, this relationship can be context-dependent. During cellular stresses like heat shock and viral infection, eIF4E is hypophosphorylated, while translation rates of specific mRNAs may vary .

What methods can researchers use to investigate eIF4E-binding protein interactions with eIF4E antibodies?

eIF4E-binding proteins (4E-BPs) are critical regulators of translation initiation. To study these interactions:

• Co-immunoprecipitation (Co-IP) approach:

  • Use eIF4E antibodies to immunoprecipitate protein complexes

  • Analyze binding partners by Western blot or mass spectrometry

  • Consider native lysis conditions (non-denaturing buffers) to preserve protein-protein interactions

  • Different detergent fractions can isolate distinct complexes (e.g., digitonin vs. Triton X-100)

• RNP isolation/mass spectrometry:

  • This approach has successfully identified cofactors of eIF4E mRNA export including LRPPRC

  • Determine whether interactions are RNA-dependent by including RNase treatment controls

  • Add heparin to immunoprecipitations to confirm specificity of interactions

• In vitro binding assays:

  • Use recombinant eIF4E coupled to sepharose beads to capture binding partners

  • Test competition with synthetic peptides containing known eIF4E-binding motifs

  • Mutational analysis of binding sites can define interaction requirements

• Distinguishing between binding sites:

  • The critical W106 residue in eIF4E is required for interaction with the canonical eIF4E-binding motif

  • Mutation of W106A can help determine whether interactions depend on this canonical binding site

  • Cup protein interaction with eIF4E demonstrates the importance of multiple binding sites that can be distinguished through specific mutations (Y342A vs. L379A/L383A)

• Functional translation assays:

  • Test whether identified binding partners block eIF4G binding to eIF4E

  • Compare wild-type and mutant binding proteins for their effects on translation

These approaches have revealed important insights, such as how Cup protein in Drosophila functions by blocking eIF4G binding to eIF4E, thereby repressing translation of specific mRNAs .

How can researchers effectively use eIF4E antibodies to study its role in mRNA export?

eIF4E plays a significant role in mRNA export that is distinct from its translation function. To investigate this function:

• Subcellular fractionation protocols:

  • Separate nuclear and cytoplasmic compartments using differential detergent extraction

  • Use Triton X-100 fractions enriched in export-competent ribonucleoprotein particles (RNPs)

  • Verify fraction purity using markers like hnRNP C1/C2 (non-shuttling nuclear proteins)

• RNA immunoprecipitation (RIP) approach:

  • Use eIF4E antibodies to immunoprecipitate associated mRNAs from nuclear fractions

  • Analyze bound mRNAs by RT-qPCR or RNA sequencing

  • Focus on transcripts containing the eIF4E-sensitivity element (4E-SE)

  • Compare results with controls lacking 4E-SE elements

• Protein-RNA interaction analysis:

  • Investigate co-factors like LRPPRC that associate with 4E-SE-containing mRNAs

  • Use RNA pull-down with 4E-SE as bait to capture associated proteins

  • Perform knockdown studies of cofactors to assess their impact on eIF4E-mRNA interactions

• Export pathway characterization:

  • The eIF4E export RNP is distinct from the bulk mRNA export pathway

  • eIF4E-sensitive mRNAs typically do not associate with general mRNA export factors like TAP/NXF1 or REF/Aly

  • Instead, look for interactions with CRM1, hnRNP A1, DDX3, and UAP56

• mRNA maturation analysis:

  • Early maturation steps of eIF4E-sensitive mRNAs appear similar to other mRNAs

  • Both LacZ and LacZ-4E-SE transcripts associate with hnRNPA1 and CBP80 in post-TX fractions

  • Differences become apparent in TX-100 fractions where 4E-SE-containing transcripts preferentially associate with eIF4E and LRPPRC

This research has demonstrated that eIF4E-mediated mRNA export represents a specialized pathway distinct from bulk mRNA export, enabling differential regulation of specific mRNAs at the export level.

What are the key methodological considerations when using eIF4E antibodies in cancer research?

eIF4E is considered a promising anticancer target due to its role in oncogene-driven protein synthesis. When using eIF4E antibodies in cancer research:

• Expression level analysis:

  • Compare eIF4E levels across cancer types and normal tissues

  • In AML, eIF4E is elevated 3-10 fold in M4/M5 subtypes but generally not in other AML subtypes or normal hematopoietic cells

  • Standardize quantification methods across sample types

• Transcriptional regulation studies:

  • Use Chromatin Immunoprecipitation (ChIP) to study transcription factor binding to the eIF4E promoter

  • Electrophoretic Mobility Shift Assays (EMSA) can validate specific binding elements

  • For NF-κB-mediated regulation, examine all four κB sites in the EIF4E promoter

• Phosphorylation analysis in cancer contexts:

  • Compare phosphorylation patterns between normal and malignant cells

  • Correlate with activation status of upstream kinases (MNK1/2)

  • Monitor changes in response to targeted therapies

• Target engagement studies:

  • When testing inhibitors of eIF4E, measure binding with techniques like cellular thermal shift assays

  • Fragment-based screening has identified novel ligand-binding sites with previously unknown function

  • Low nM tool compounds can disrupt the eIF4E:eIF4G interaction and inhibit translation

• Combining with degrader technology:

  • Targeted protein degradation coupled with genetic rescue using eIF4E mutants

  • This approach has shown that disruption of both canonical eIF4G and non-canonical binding sites may be required for strong cellular effects

These methodologies can help researchers better understand eIF4E dysregulation in cancer and develop potential therapeutic approaches targeting this critical factor.

What are common sources of variability when using eIF4E antibodies, and how can these be addressed?

Variability in eIF4E antibody experiments can arise from multiple sources. Here are methodological approaches to address them:

• Antibody lot-to-lot variation:

  • Validate each new lot against previous lots

  • Maintain reference samples for comparison

  • Consider creating standard curves with recombinant eIF4E

• Phosphorylation state fluctuations:

  • eIF4E phosphorylation can change rapidly during sample processing

  • Standardize time between cell harvesting and lysis

  • Include phosphatase inhibitors in all buffers

  • Process all experimental samples in parallel

• Cell state and culture conditions:

  • eIF4E function is affected by cell confluency, serum levels, and stress

  • Standardize culture conditions and harvest protocols

  • Document passage number and growth conditions

• Subcellular localization shifts:

  • eIF4E shuttles between nucleus and cytoplasm

  • Extraction methods can influence apparent distribution

  • Use multiple fractionation techniques to confirm localization patterns

  • Consider live-cell imaging to avoid fixation artifacts

• 4E-BP binding interference:

  • 4E-BPs can mask antibody epitopes on eIF4E

  • Treatment with cap analogs or competitive peptides can release 4E-BPs

  • Compare different lysis conditions that may preserve or disrupt these interactions

• Cross-reactivity with eIF4E isoforms:

  • Humans express multiple eIF4E family members (eIF4E1, eIF4E2/4EHP, eIF4E3)

  • Verify antibody specificity for the intended isoform

  • Consider using isoform-specific antibodies like the eIF4EI antiserum generated against the unique N-terminal sequence

Addressing these variables systematically will improve reproducibility and reliability of experimental results.

How can researchers optimize immunoprecipitation protocols for studying eIF4E complexes?

Immunoprecipitation of eIF4E complexes requires careful optimization to maintain physiologically relevant interactions while achieving sufficient specificity and yield:

• Lysis buffer composition:

  • Different detergents isolate distinct complexes:

    • Digitonin (0.5%) preserves interactions with translation factors like eIF4G

    • Triton X-100 (0.5%) enriches for export-competent RNPs

  • Salt concentration affects interaction stability:

    • 100-150 mM NaCl maintains most interactions

    • Higher salt (250-500 mM) may reduce non-specific binding but can disrupt weaker interactions

• Antibody selection and coupling:

  • Test multiple eIF4E antibodies targeting different epitopes

  • Consider direct coupling to beads to avoid heavy chain interference in Western blots

  • For sequential IPs, use antibodies from different species

  • Optimal antibody concentration must be determined empirically

• Bead selection and blocking:

  • Protein A/G beads work well for most mammalian IgGs

  • Pre-clear lysates with beads alone to reduce background

  • Block beads with BSA or non-immune serum to minimize non-specific binding

• RNA-dependent vs RNA-independent interactions:

  • Include RNase treatment controls to distinguish:

    • RNA-independent interactions (e.g., eIF4E with LRPPRC, PML, CRM1, DDX3)

    • RNA-dependent interactions (e.g., eIF4E with UAP56)

  • Add heparin to immunoprecipitations to confirm interaction specificity

• Elution strategies:

  • Gentle elution with excess antigen peptide

  • SDS elution for maximum recovery but potential denaturation

  • Cap analog (m7GTP) elution for functional cap-binding complexes

• Analysis of co-precipitated proteins and RNAs:

  • Western blotting for known binding partners

  • Mass spectrometry for unbiased identification of interactions

  • RT-PCR or RNA-seq for associated transcripts

This optimized approach has been successful in identifying novel components of eIF4E complexes, including the discovery of LRPPRC as a cofactor in eIF4E-mediated mRNA export .

What experimental design considerations are important when studying phospho-specific eIF4E regulation?

When investigating phosphorylation-dependent regulation of eIF4E, researchers should employ rigorous experimental designs:

• Antibody validation for phospho-specificity:

  • Confirm specificity using phosphatase treatment controls

  • Validate with phosphomimetic (e.g., S209D) and phosphodeficient (e.g., S209A) eIF4E mutants

  • Compare Western blot migration patterns of phosphorylated vs. unphosphorylated forms

• Positive and negative control conditions:

  • Positive controls: Serum stimulation or treatment with phorbol esters typically increases eIF4E phosphorylation

  • Negative controls: Serum starvation, MNK inhibitor treatment, or expression of dominant-negative MNK

  • Include mitotic cells where eIF4E is hypophosphorylated despite general increases in phosphorylation events

• Time-course designs:

  • Monitor phosphorylation dynamics after stimulation

  • Include early timepoints (minutes) to capture rapid changes

  • Extend to longer timepoints (hours) to observe adaptation

• Correlation with functional outputs:

  • Measure translation rates in parallel with phosphorylation status

  • Analyze polysome profiles to assess global translation

  • Use reporter constructs to monitor cap-dependent vs. cap-independent translation

• Context-dependent regulation:

  • Different cellular stresses yield different outcomes:

    • Heat shock and viral infection correlate with reduced eIF4E phosphorylation

    • Mitosis also shows hypophosphorylation when translation rates are low

  • Document cell cycle phase, confluency, and stress status

• Kinase and phosphatase inhibitor controls:

  • Include MNK1/2 inhibitors (e.g., CGP57380) to block eIF4E phosphorylation

  • Test phosphatase inhibitors to prevent dephosphorylation

  • Use kinase-dead mutants as genetic controls

This strategic approach allows researchers to establish causative relationships between eIF4E phosphorylation status and functional outcomes in different cellular contexts.

How can eIF4E antibodies be used in combination with fragment-based screening approaches for drug discovery?

Recent advances have combined antibody-based techniques with fragment-based screening to identify novel therapeutic targets on eIF4E:

• Fragment screening methodology:

  • Fragment libraries can be screened against eIF4E to identify novel binding sites

  • This approach has successfully identified ligand-binding sites with previously unknown function

  • Antibodies can be used to validate binding through competition assays or conformational changes

• Structure-based design workflow:

  • Initial fragment hits can be developed into higher-affinity compounds

  • Recent work has yielded low nM tool compounds (K₁ = 0.09 μM; LE 0.38) that disrupt eIF4E:eIF4G interaction

  • Antibodies can verify target engagement in cellular contexts

• Functional validation approaches:

  • Compounds that bind eIF4E can be tested for:

    • Disruption of eIF4E:eIF4G interaction

    • Inhibition of translation in cell lysates

    • Target engagement with eIF4E in intact cells (EC₅₀ = 2 μM)

  • Antibodies provide critical readouts for these assays

• Combining with targeted protein degradation:

  • Targeted degradation coupled with genetic rescue using eIF4E mutants

  • This combined approach has revealed that disruption of both canonical eIF4G and non-canonical binding sites is likely required for strong cellular effects

  • Antibodies can monitor degradation kinetics and efficiency

• Future applications:

  • Development of bifunctional molecules targeting eIF4E

  • Creation of degrader compounds linking eIF4E ligands to E3 ligase recruiters

  • Antibodies for measuring pharmacodynamic effects in preclinical models

This integrated approach demonstrates how antibody-based techniques can complement fragment-based drug discovery to probe protein function in complex biological systems, potentially leading to novel therapeutic strategies.

What are the considerations for using eIF4E antibodies in studying its role in AML and other hematological malignancies?

eIF4E is dysregulated in certain hematological malignancies, particularly acute myeloid leukemia (AML). When using eIF4E antibodies in this context:

• Expression pattern analysis:

  • eIF4E is elevated 3-10 fold specifically in M4/M5 AML specimens but generally not in other AML subtypes

  • Compare with expression in normal hematopoietic cells (CD34+ cells, granulocytes, monocytes)

  • Use standardized quantification methods across patient samples

• Transcriptional regulation studies:

  • eIF4E is a direct transcriptional target of NF-κB in hematopoietic cells

  • Promoter analysis techniques:

    • ChIP assays to assess transcription factor binding

    • EMSA to validate specific binding elements

    • Promoter reporter assays to measure activity

• NF-κB regulatory complex characterization:

  • The human eIF4E promoter contains multiple NF-κB binding sites

  • cRel/p65 heterodimers bind these promoter elements

  • Use supershift analysis with antibodies against p50, p65, and c-Rel to characterize complex composition

• Functional studies in primary patient samples:

  • Introduction of dominant negative IκB-SR (which blocks NF-κB nuclear translocation) leads to reduced growth of primary AML cells

  • Measure effects on eIF4E expression levels using antibody-based detection

  • Correlate with functional outcomes like proliferation and survival

• Therapeutic target validation:

  • Monitor eIF4E levels and activity in response to NF-κB pathway inhibitors

  • Test combination approaches targeting both expression and function

  • Consider eIF4E as a biomarker for patient stratification

These methodological approaches can help researchers better understand how eIF4E dysregulation contributes to AML pathogenesis and potentially identify new therapeutic strategies for specific AML subtypes.

How can researchers integrate antibody-based eIF4E data with other types of data for comprehensive pathway analysis?

Integrating eIF4E antibody data with complementary datasets enables more comprehensive understanding of translation regulation networks:

• Multi-omics integration approaches:

  • Combine eIF4E protein expression/phosphorylation data (antibody-based) with:

    • Transcriptomics (RNA-seq) to correlate with mRNA levels

    • Translatome analysis (ribosome profiling) to assess functional impact

    • Proteomics to evaluate downstream effects

    • Interactome studies to map protein-protein interactions

• Correlation analysis with clinical parameters:

  • Link eIF4E expression/activation patterns with:

    • Patient outcomes in cancer studies

    • Response to therapies targeting translation

    • Disease subtypes and progression stages

• Pathway modeling:

  • Position eIF4E within signaling networks:

    • Upstream regulators (mTOR, MAPK pathways)

    • Parallel pathways (4E-BP regulation, eIF2α phosphorylation)

    • Downstream effects (cap-dependent vs. cap-independent translation)

  • Construct models incorporating positive/negative feedback loops

• Bioinformatic analysis of eIF4E-sensitive transcripts:

  • Compare transcripts containing the eIF4E-sensitivity element (4E-SE)

  • Analyze 5' UTR structures of preferentially translated mRNAs

  • Identify common motifs in eIF4E-regulated transcripts

• Single-cell approaches:

  • Combine antibody-based detection of eIF4E with single-cell RNA-seq

  • Map heterogeneity in eIF4E activity across cell populations

  • Correlate with cell state transitions

• Dynamic systems analysis:

  • Time-course studies of eIF4E phosphorylation after stimulation

  • Correlation with downstream effector activation

  • Mathematical modeling of translation initiation dynamics

This integrated approach provides a systems-level view of eIF4E function and can reveal emergent properties not apparent from single-method investigations.

What standards should researchers follow when reporting antibody-based eIF4E research?

To ensure reproducibility and comparability of eIF4E antibody-based research, adherence to reporting standards is essential:

• Antibody validation and characterization:

  • Report complete antibody information:

    • Commercial source, catalog number, lot number

    • For custom antibodies: immunogen, host species, purification method

    • Validation methods used (Western blot, IP-MS, knockout controls)

  • Include antibody dilutions and incubation conditions

• Sample preparation details:

  • Cell culture conditions (media composition, serum percentage, cell density)

  • Lysis buffers (detergent type and concentration, salt concentration)

  • Inclusion of phosphatase/protease inhibitors

  • Sample processing timeline (time from stimulation to lysis)

• Controls and normalization:

  • Document positive and negative controls

  • For phospho-specific studies, include total eIF4E controls

  • Normalization method (loading controls, housekeeping proteins)

  • Statistical methods for quantification

• Experimental design transparency:

  • Biological replicate number and definition

  • Technical replicate strategy

  • Randomization and blinding procedures (where applicable)

  • Power analysis for sample size determination

• Image acquisition and processing:

  • Image capture settings (exposure times, gain settings)

  • Software used for analysis and quantification

  • Any image manipulations (contrast adjustment, cropping)

  • Representative images alongside quantification

• Interaction studies specifics:

  • RNase treatment details for RNA-dependent interactions

  • Buffer conditions affecting complex stability

  • Elution methods for immunoprecipitation

  • Confirmation with reciprocal IP where possible

Following these reporting standards will enhance reproducibility across laboratories and facilitate meta-analysis of eIF4E research findings.

What are the emerging technologies that might enhance eIF4E antibody applications in research?

Several cutting-edge technologies show promise for expanding eIF4E antibody applications:

• Proximity-based labeling approaches:

  • BioID or TurboID fusion with eIF4E to identify transient interactors

  • APEX2-based approaches for spatially restricted labeling

  • These methods can capture dynamic interactions often missed by traditional immunoprecipitation

  • Antibodies remain essential for validation of hits

• Single-molecule imaging techniques:

  • Super-resolution microscopy to visualize eIF4E in translation initiation complexes

  • Single-molecule tracking to monitor eIF4E dynamics in living cells

  • FRET-based sensors to detect eIF4E conformational changes upon binding

  • Antibody fragments or nanobodies may offer advantages for these applications

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated eIF4E antibodies for high-dimensional analysis

  • Simultaneous detection of multiple signaling pathways

  • Single-cell resolution of eIF4E activation in heterogeneous populations

  • Correlation with cell state markers

• Spatial transcriptomics integration:

  • Combine eIF4E antibody detection with spatial mapping of translation

  • Visualize localized translation in subcellular compartments

  • Map eIF4E activity in tissue microenvironments

• Nanobody and alternative binding protein development:

  • Engineered single-domain antibodies with improved tissue penetration

  • Designed ankyrin repeat proteins (DARPins) targeting specific eIF4E conformations

  • Aptamer-based detection systems for live-cell applications

• CRISPR-based screening with antibody readouts:

  • Genome-wide screens for factors affecting eIF4E expression/phosphorylation

  • High-content imaging with eIF4E antibodies as primary readout

  • Correlation with functional phenotypes

These emerging technologies, when combined with traditional antibody applications, will provide unprecedented insights into eIF4E function and regulation in health and disease.

What are the most important unanswered questions in eIF4E biology that antibody-based research might address?

Despite extensive research, several key questions about eIF4E biology remain unanswered:

• Phosphorylation function:

  • The precise role of eIF4E phosphorylation remains incompletely understood

  • Unphosphorylated eIF4E can stimulate translation in vitro and bind the mRNA cap

  • Antibodies specific to different phosphorylation states will be crucial to resolve context-specific functions

• Substrate selectivity mechanisms:

  • How eIF4E preferentially enhances translation of specific mRNAs

  • The role of 5' UTR structure and sequence elements

  • Antibodies to study eIF4E in complex with different mRNA classes

• Nuclear vs. cytoplasmic functions:

  • The mechanism by which eIF4E selectively exports certain mRNAs

  • How export and translation functions are coordinated

  • Antibodies for tracking eIF4E shuttling between compartments

• Condition-specific binding partners:

  • How interaction networks reconfigure during development, stress, and disease

  • Identification of cell-type specific regulators

  • Antibodies for tissue-specific interactome studies

• Therapeutic targeting approaches:

  • How to specifically inhibit oncogenic functions while preserving essential activities

  • Biomarkers to predict response to eIF4E-directed therapies

  • Antibodies to assess target engagement in preclinical models

• Non-canonical binding sites:

  • Function of recently identified non-canonical binding sites on eIF4E

  • How these sites influence protein-protein interactions and activity

  • Conformational antibodies to detect occupied vs. unoccupied states